Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. “These data continue to support our view that MCLA-129 is a very active drug, and that our Biclonics® platform really can create clinically active drugs for patients with cancer. We plan to start a cohort investigating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC later this year,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “We continue to evaluate MCLA-129 with a focused investment and remain interested in a partnership to resource the further development of this asset.” Poster present
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $99.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target lowered by analysts at Bank of America Co. from $80.00 to $76.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $54.00 to $67.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target raised by analysts at BMO Capital Markets from $84.00 to $91.00. They now have an "outperform" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target raised by analysts at Truist Financial Co. from $69.00 to $88.00. They now have a "buy" rating on the stock.MarketBeat
MRUS
Earnings
- 5/8/24 - Beat
MRUS
Sec Filings
- 6/17/24 - Form 144
- 6/12/24 - Form 4
- 6/6/24 - Form 4
- MRUS's page on the SEC website